QR-Code

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus AB...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Pedro Giavina-Bianchi, MD, PhD, Eric Cua, MD, Karine Risso, MD, Véronique Mondain, MD, Anaïs Vissian, MSc, Cécile Joie, MSc, Philippe Pouletty, MD, Paul Gineste, PharmD, Hartmut J. Ehrlich, MD, PhD, Jorge Kalil, MD, PhD
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2023-11-01
Schriftenreihe:Journal of Allergy and Clinical Immunology: Global
Schlagworte:
ABX464
obefazimod
miR-124
COVID-19
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2772829323000656
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge